Forsyth Medical Center participating in Avastin trial for new glioblastoma patients
Winston-Salem, N.C. The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is participating in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the brain or spinal cord.
Forsyth Regional Cancer Center (FRCC) is participatin...
Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
TORONTO, Feb. 26 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc.,
a biopharmaceutical company dedicated to the development and
commercialization of cancer therapies, today announced that Phase II data
on the Company's Neuradiab product candidate a...
Tailoring glioblastoma therapies: 1 size does not fit all
An upcoming G&D paper from Dr. Azad Bonni and colleagues at Harvard
Medical School lends new insight into how the unique genetic signature of glioblastoma
tumors affects treatment efficacy - a finding with promising hope for the therapeutic targeting of the leading cause of cancer-related deaths ...
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
Small molecule drug inhibits key DNA repair mechanism involved in resistance
DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therap...
Paradigm shift: Switch for programmed cell death promotes spread of glioblastoma
This release is available in German .
Malignant tumors have usually lost their ability to destroy themselves by programmed cell death, or apoptosis. Therefore, tumors are often resistant to chemotherapy or radiation therapy, whose effect is based on forcing tumor cells to commit suicide.
Adult Glioblastoma: Optimal Approaches to a Challenging Diagnosis
VOORHEES, N.J., Aug. 4 /PRNewswire/ -- Treatment of glioblastoma
(GBM), the most common type of glioma, presents many challenges. More than 50% of patients die of disease progression within 18 months of diagnosis. C...
National Cancer Coalition Announces Angel Grant Recipients
...y at the University of Chicago's Comer Children's Hospital. His Angel Grant will be used to further his investigations of the biology of pediatric glioblastoma
multiforme (GBM) brain tumors and their treatment.
The National Cancer Coalition implemented its Angel Grant program to provide seed funding ...
Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved
...rapeutic vaccines in development for cancer include Merck KGaA's Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer's CDX-110 for glioblastoma
multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing...
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29
...ng Pipeline: The Company provided an update on several of its clinical programs:
AMG 102: In Phase 2 studies, limited efficacy was seen in glioblastoma
multiforme and renal cell carcinoma when AMG 102 was administered in monotherapy, but the effect size was not large enough to warrant moving forward w...
Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid
...l candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma
multiforme. Bradmer initiated enrollment of primary GBM patients in a Phase III multi-center clinical trial of Neuradiab. Neuradiab has been granted O...
glioblastoma in Medical Technology
Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
- PFS data from Neuradiab(TM) compares favorably to data from other
TORONTO, July 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc.
(TSX: BMR), a biopharmaceutical company dedicated to the development and
commercialization of cancer therapies, today release...
Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that Dr.
Jie Lu and Dr. Zhengping Zhuang of the Surgical Neurology Branch (SNB),
National Institute of Neurological Disorders and Stroke (NINDS), National
Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
ZFN Modified Cells Show Glioblastoma
Killing in the Presence of Dexamethasone in Mouse Tumor Model
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
(Nasdaq: SGMO ) today announced the presentation of positive data in a mouse
tumor model from its ZF...
Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
Celldex also receives approval from Health Canada to open clinical sites and establishes a collaboration with the National Cancer Institute
PHILLIPSBURG, N.J., Dec. 7 /PRNewswire/ -- Celldex Therapeutics
announced today that the U.S. Food and Drug Administration (FDA) has
granted orphan drug...
Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
LOS ANGELES, Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp.
and the European Organisation for the Research and Treatment of Cancer
(EORTC) announced long-term follow-up results from the landmark Phase III
trial conducted by the EORTC and the National Cancer Institute of Canada
MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
REHOVOT, Israel and JERSEY CITY, New Jersey, September 18
/PRNewswire-FirstCall/ -- - A Collaborative Study by Scientists at the
Weizmann Institute of Science and Scientists at Sheba Medical Center, With
the aid of Rosetta Genomics, Demonstrated That Overexpression of miR-451
Inhibited Growth ...
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
PHILLIPSBURG, N.J., Jan. 7 /PRNewswire/ -- Celldex Therapeutics
announced today that the U.S. Food and Drug Administration (FDA) has
granted Fast Track designation to Celldex's CDX-110 for the treatment of
EGFRvIII expressing Glioblastoma
Multiforme (GBM). GBM is the most common
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients
With Recurrent Glioblastoma (GBM)
Phase II GBM study presented at ASCO with cediranib - a selective
VEGF signaling inhibitor - shows over a quarter of patients alive
and progression- free at six months(1)
CHICAGO, June 04, 2007 /PRNewswire/ -- Data for the
investigational agent cediranib (AZD2171) were presented today at
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
...oard #J13; GU General Poster Session, May 31, 2:00 p.m.-6:00 p.m.
Fiveash J, et al. NABT-0702: A phase II study of AT-101 in recurrent glioblastoma
multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May 30, 8:00 a.m.-12:00 p.m.
Heist R, et al. A phase I/II...
Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
...ther long-term follow-up data, for the
second half of 2008, from its prior Phase I and Phase I/II clinical trials
with DCVax(R)-Brain in patients with glioblastoma
multiforme, the most rapid
and lethal type of brain cancer. During the update period from June 15, 2008,
through January 1, 2009, none of the twenty p...
glioblastoma in Biological News
Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
Washington, DC Cancer researchers at Georgetown University's Lombardi Comprehensive Cancer Center have successfully tested a small, engineered antibody they say shuts down growth of human glioblastoma
tumors in cell and animal studies. Glioblastoma
is the deadliest of brain cancers; there is no e...
Salk researchers develop novel glioblastoma mouse model
LA JOLLA, CAResearchers at the Salk Institute for Biological Studies have developed a versatile mouse model of glioblastomathe most common and deadly brain cancer in humansthat closely resembles the development and progression of human brain tumors that arise naturally.
"Mouse models of human ...
GUMC researchers find gene function 'lost' in melanoma and glioblastoma
Washington, D.C. Researchers at Georgetown University Medical Center have found a gene they say is inactivated in two aggressive cancers malignant melanoma, a form of skin cancer, and glioblastoma
multiforme, a lethal brain tumor. They add that because this gene, known as PTPRD, has recently bee...
A crystal ball for brain cancer?
... common and deadly form of adult brain tumor, striking 12,000 Americans a year. Despite therapy with surgery, radiation and chemotherapy, the average glioblastoma
patient lives only 12 to 15 months after diagnosis.
Survival rates drop even lower if the tumor returns. Conventional therapies produce little b...
TGen researchers discover possible way to block the spread of deadly brain tumors
...a , an international journal of cancer research.
Cancer cell movement and rapid division are key characteristics of malignant brain tumors known as glioblastoma
multiforme, or GBM.
Dr. Michael Berens, Director of TGen's Cancer and Cell Biology Division, said the recent findings are a major step toward devis...
UNC study: Scientists identify chemical compound that may stop deadly brain tumors
...ed how a particular gene mutation contributes to tumor growth.
The findings and potential treatment apply to a type of brain tumor called secondary glioblastoma
multiforme (GBM). GBMs are part of a larger group of brain tumors called malignant gliomas, which is the type of cancer Senator Edward Kennedy suffers...
UC Davis researchers find molecule that targets brain tumors
...e for effectively treating an incurable cancer.
is the most common and aggressive type of primary ...ability to target brain cancer by implanting human glioblastoma
cells both beneath the skin and in the brains of m...that the molecule did preferentially bind to human glioblastoma
cells in both locations.
"This outcome gives us...
Breast cancer genome shows evolution, instability of cancer
...udy is one of several that have appeared this year. For example, the BCM Human Genome Sequencing Center also took part in determining the sequences of glioblastoma
(a brain cancer) and lung adenocarcinoma. All occurred under the umbrella of the Cancer Genome Atlas Project funded by the National Institutes of Heal...
Collaboration between researchers yields more comprehensive portrait of brain cancer
...ch Institute of the National Institutes of Health. glioblastoma
is the most common and most aggressive of the prim... U.S. Senator Edward M. Kennedy was diagnosed with glioblastoma
earlier this year.
Drs. Devin Absher and Rick...ine the molecular differences between a normal and glioblastoma
genome. The data were analyzed in collaboration wi...
AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting
...sic scientists and translational researchers.
Angiogenic factors that increase risk for breast cancer
Genetic markers for glioblastoma
New data on nanotechnology as a cost effective diagnostic method
More accurate tools for diagnosing myeloproliferative neoplasia
glioblastoma in Biological Technology
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
... anti-cancer drugs. In mouse models, LB-1.2 plus Temozolomide caused complete regression without recurrence in 50 % of animals bearing tumors of human glioblastoma
multiforme (GBM), the most common and aggressive brain tumor of adults, and also, marked regression of neuroblastoma, the most common cancer of childr...
Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
...ne labeling is already being used for the production of Peregrine's radiolabeled antibody Cotara(R), currently in Phase II trials for the treatment of glioblastoma
multiforme, a deadly form of brain cancer.
Radiolabeled drugs are important for the diagnosis and treatment of multiple cancers. However, the la...
YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
...III trial in newly diagnosed pediatric pontine glioma has been concluded and we anticipate that recruitment in our randomised Phase III trial in adult glioblastoma
grade IV will be completed in 2009. We are confident that data from these trials, along with data that will come from our placebo controlled randomise...
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
...e being developed as a potential new treatment for glioblastoma
multiforme (GBM), a deadly form of brain cancer. ...linical study, a subset of patients with recurrent glioblastoma
treated with Cotara achieved a median survival of ...us and fast track designation for the treatment of glioblastoma
multiforme and anaplastic astrocytoma by the U.S. ...
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
...itute (NCI) sponsored Phase II study of AT-101 as monotherapy for recurrent glioblastoma
multiforme (GBM), the most aggressive form of brain cancer, were also prese... Fiveash J, et al. NABT-0702: A phase II study of AT-101 in recurrent glioblastoma
multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May ...
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
...ings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma
multiforme and multiple myeloma.
Dr. Gregg Smith Mr. Andrew Macdonald
Director, Drug Developme...
Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR
...nday, April 20, 2009, 1:00 pm - 5:00 pm)
-- Dual targeting of the receptor tyrosine kinase EGFRvIII and HGF:c-Met
signaling in models of glioblastoma
Overview: Examined the effect of combining a fully human neutralizing
antibody targeting the HGF:c-Met axis (AMG 102)...
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
...'s future development when we
receive the results of an ongoing 113 patient Phase 2 clinical trial of MGd
combined with radiation plus temozolomide in glioblastoma
This trial is being conducted by the Radiation Therapy Oncology Group (RTOG)
with results expected in late 2010."
Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
...road platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in glioblastoma
multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III tria...
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
..., with the aid of Rosetta Genomics, has
demonstrated that a microRNA first disclosed by the company increased the
efficacy of Imatinib (Gleevec(R)) in glioblastoma
(GBM), the most common and
most aggressive type of primary brain tumor.
Conferences and Events
Rosetta Genomics presented at the followi...
glioblastoma in Biological Dictionary
...ophosmin/B23" ... A non- tumor suppressor role for basal p19ARF in ... : Frequent mutations or deletions of PTPRD are found in both melanoma and glioblastoma
multiforme. ... Suppressor of Melanoma Tumor Growth Identified ... Arf Tumor Suppressor . Lifestyle, fitness & health information abou...